Structural basis for the blockage of IL-2 signaling by therapeutic antibody basiliximab
Du, J., Yang, H., Zhang, D., Wang, J., Guo, H., Peng, B., Guo, Y., Ding, J.(2010) J Immunol 184: 1361-1368
- PubMed: 20032294 
- DOI: 10.4049/jimmunol.0903178
- Primary Citation of Related Structures:  
3IU3 - PubMed Abstract: 
IL-2 signaling plays a central role in the initiation and activation of immune responses. Correspondingly, blockage of this pathway leads to inhibition of the immune system and would provide some therapeutic benefits. Basiliximab (Simulect), a therapeuti ...